DNA Vaccines Market Growth Analysis

Market Insights

The DNA Vaccines Market was estimated at US$ 433 million in 2021 and is expected to grow at a CAGR of 6.18% during 2022-2028 to reach US$ ~654 million in 2028.

Wish to get a free sample? Register Here

What is a DNA vaccine?

A DNA vaccine is a tiny, circular DNA plasmid that, under the direction of a promoter, encodes one or more protein antigens in order to trigger a particular immune response against disease. The third generation of vaccines, known as DNA vaccines, was created expressly to address the undesirable characteristics of traditional immunizations. The population is becoming more susceptible to infectious diseases, and the number of infections that are resistant to antibiotics has increased, necessitating the development of long-lasting vaccines that are both efficient and affordable.

Market Dynamics

The vaccine industry is transitioning quickly from an approach based primarily on empirical data to one based on rational design. Rational design approaches are made possible by recent advances in molecular biology, DNA synthesis, and immunobiology. These methods enable highly focused vaccines that target certain epitopes. New vaccines, including a new class of therapeutic vaccines, are created as a result, covering a larger variety of diseases than was previously possible. These new technologies open up a sizable new market for pharmaceutical companies by enabling the discovery and development of high-value vaccines for cutting-edge uses.

The growth in the incidence of cancer and infectious illnesses in humans and animals, as well as the rising demand for DNA vaccines due to their benefits including reduced infection risk, simplicity of transportation, and stability at room temperature, are the primary reasons driving the DNA vaccines market. Additionally, the demand for efficient and affordable vaccinations like DNA vaccines, which would provide long-lasting protection, has been spurred by the rise in the number of bacteria that are resistant to antibiotics.

However, the lack of immunogenicity linked to DNA vaccines may impede market expansion. Furthermore, the market's expansion is anticipated to be constrained by incomplete knowledge of the effects of DNA vaccines on humans. For companies in the DNA vaccines market, however, there are a number of variables that are anticipated to provide lucrative growth prospects. These include the development of innovative vaccines employing DNA technology and significant growth potential in underdeveloped emerging nations.

The vaccine industry is transitioning quickly from an approach based primarily on empirical data to one based on rational design. Rational design approaches are made possible by recent advances in molecular biology, DNA synthesis, and immunobiology. These methods enable highly focused vaccines that target certain epitopes. New vaccines, including a new class of therapeutic vaccines, are created as a result, covering a larger variety of diseases than was previously possible. These new technologies open up a sizable new market for pharmaceutical companies by enabling the discovery and development of high-value vaccines for cutting-edge uses.

Due to the widespread prevalence of diseases, there has been a huge growth in the need for vaccines during the past several years. Due to the excellent effectiveness of these vaccinations in avoiding infectious diseases, market participants have the opportunity.

DNA vaccinations might make it easier to eradicate diseases including cancer, hepatitis, HIV, and others. Additionally, as travelers have a higher-than-average risk of contracting numerous diseases, vaccinations are generally advised for them. For instance, vaccinations against cholera, hepatitis, meningitis, Japanese encephalitis, typhoid fever, yellow fever, rabies, polio, and tickborne encephalitis are recommended for travelers. The prevalence of the aforementioned diseases in a few popular tourist places has increased the demand for DNA vaccines worldwide.

Routine immunization against diseases like cholera, dengue, diphtheria, tetanus, pertussis (DTP), Haemophilus influenza type B, hepatitis A, hepatitis B, and the human papillomavirus is also advised. The demand for DNA vaccines is also increased by an increase in the prevalence of influenza and pneumococcal infections. Furthermore, DNA vaccines offer both humoral and cell-mediated protection, having a broad range of applications. The three main clinical objectives for DNA vaccines are HIV, papillomavirus, and influenza. Cervical cancer, which is brought on by HPV, is the third most common cause of death worldwide, according to the World Health Organization. Gardasil (Merck) and Cervarix (GlaxoSmithKline), two preventive HPV vaccinations, were created in 2006 and 2009, respectively.

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:

• DNA vaccines target a variety of conventional pharmaceutical markets, including infectious disorders, allergies, and malignancies. With the release of Gardasil by Merck, the larger vaccination business demonstrated its ability to produce goods with novel uses and potential blockbuster sales. DNA vaccines are ready to adopt this new business strategy and create a large market opportunity.
• The development of DNA vaccines is being driven by new bio- and nanotechnologies. Emerging delivery methods like electroporation (EP), novel vaccine formats like DNA prime-adenovector boost, and novel molecular adjuvant technologies are particularly crucial for DNA vaccines to realize their full potential. These technologies are giving people the tools they need to be more effective.
• DNA vaccine development has already advanced significantly. For a wide range of disorders, there are currently close to 100 human clinical studies active, and there is a substantial pipeline of preclinical initiatives. Today, applications for animal health and research tools make up a small but essential business niche.

Segments Analysis

By Product Type

The market is further segmented into Oncept, West Nile-Innovator, and Apex-IHN.

By Type

The DNA vaccines market has been divided into therapeutic vaccines and prophylactic vaccines.

By End-User Type

The market is segmented into hospitals, clinics, and others.

Regional Analysis

The DNA vaccines market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Key Players

The market for DNA vaccines is highly competitive. The state of the economy and government assistance have a direct impact on the expansion of businesses. Based on their product's quality and market penetration in both the target and growing markets, these companies distinguish their DNA vaccines driver in the industry. Furthermore, recent important mergers and acquisitions in the sector have had a big impact on the dynamics of competition. For instance:

• In August 2021, The Drug Controller General of India (DCGI) has granted Zydus Cadila Emergency Use Authorization (EUA) for ZyCoV-D, the first DNA-based COVID-19 vaccine produced entirely in India and approved for use in humans, including children and adults 12 years of age and older. Mission COVID Suraksha, which was created in collaboration with the Department of Biotechnology, Government of India, and carried out by BIRAC.
• Eli Lilly signed a contract in January 2021 with GlaxoSmithKline and biotech partner Vir for the testing of their emergency-cleared COVID-19 antibody bamlanivimab 700 mg in combination with GSK/investigational Vir's treatment VIR-7831 (also known as GSK4182136) 500 mg.

The overall competitive landscape has been affected due to these strategic activities. The following are the major players in the DNA vaccines market:

• BOEHRINGER INGELHEIM GmbH (Merial)
• ELI-LILLY (Novartis Animal Health)
• GeneOne Life Science
• Genexine, Inc.
• GEOVAX LABS, INC
• Inovio Pharmaceuticals (VGX Animal Health)
• Takara Holdings (Takara Bio)
• VIATRIS INC. (Rottapharm Biotech)
• ZOETIS INC. (Fort dodge Animal Health)
• Zydus Cadila 

Research Methodology

This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s DNA vaccines market realities and future market possibilities for the forecast period. The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market. The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com